Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime Sells 8,000 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $88.78, for a total value of $710,240.00. Following the completion of the sale, the chief financial officer now directly owns 109,491 shares in the company, valued at $9,720,610.98. This trade represents a 6.81 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Andrew Guggenhime also recently made the following trade(s):

• On Friday, October 18th, Andrew Guggenhime sold 42,000 shares of Vaxcyte stock. The stock was sold at an average price of $115.39, for a total value of $4,846,380.00.

Vaxcyte Stock Performance

NASDAQ:PCVX traded up $0.46 during trading hours on Thursday, reaching $86.21. The stock had a trading volume of 1,143,054 shares, compared to its average volume of 908,236. The company has a 50 day moving average price of $99.77 and a two-hundred day moving average price of $92.07. Vaxcyte, Inc. has a 52 week low of $53.83 and a 52 week high of $121.06. The stock has a market capitalization of $10.74 billion, a PE ratio of -18.74 and a beta of 0.94.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period in the prior year, the company posted ($0.91) EPS. Equities research analysts predict that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Institutional Investors Weigh In On Vaxcyte

Several institutional investors have recently made changes to their positions in the company. Riverview Trust Co bought a new position in shares of Vaxcyte in the third quarter worth about $27,000. Fifth Third Bancorp purchased a new stake in Vaxcyte in the 2nd quarter valued at about $35,000. Blue Trust Inc. grew its stake in Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after acquiring an additional 93 shares in the last quarter. Quest Partners LLC bought a new stake in shares of Vaxcyte during the second quarter valued at approximately $70,000. Finally, Meeder Asset Management Inc. boosted its holdings in shares of Vaxcyte by 1,007.9% in the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after purchasing an additional 635 shares during the period. Institutional investors own 96.78% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on PCVX shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Leerink Partners raised their price target on Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 3rd. Jefferies Financial Group upped their price objective on Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. BTIG Research raised their price objective on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Finally, Bank of America increased their price target on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.